Board summary
Key figures
38,799
Registered population
61.2% aged 18–64
17.6%
Aged 65+
ICB 19.0% · England 17.9%
3.8%
Ethnic minority (non-White)
1.6% Asian · England 9.6%
30.7%
In IMD quintile 1
ICB 31.9% · England 21.0%
~10,865
Core20 residents (est.)
Resident basis; registered basis ~12,235 · see page 3
6,629
Hypertension register
+4.31% in 3 yrs · England +5.60%
385
SMI register
10.2% of Cheshire West and Chester (LAD)'s
1,165
COPD register
Reviews -2.26% in 3 yrs
Forecast to 2030
7,448
Hypertension patients, 2030
+819 on today
78.3%
QRISK ≥20% on statins, 2030
+3.21pp over 3 yrs
4.5%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma annual reviews trail England.
Annual asthma reviews fell 4.5 pp over 2023 to 2025 to 61.7% (England 65.7%, +2.8 pp), leaving about 1,100 patients unreviewed.
Diabetes control and SMI checks lag.
Non-frail diabetes HbA1c control is 50.4% (England 57.4%), while SMI blood pressure checks fell 8.9 pp to 79.9% (England 83.4%, +4.4 pp).
Current lipid and hypertension treatment above England.
Lipid-lowering therapy in QRISK ≥ 20% reaches 71.4% (England 63.6%) and hypertension control is 72.2% (England 70.3%), despite hypertension control falling 4.9 pp.
Population, age and ethnicity
A younger registered population of 38,799 patients with 96.2% White Census residents
Winsford PCN serves 38,799 registered patients across five practices. The registered population is younger than benchmarks: 21.1% (8,207 patients) are aged 0-17, compared with 18.5% in Cheshire West and Chester (LAD), 19.2% in NHS Cheshire and Merseyside Integrated Care Board, and 19.6% in England. Patients aged 65+ comprise 17.6% (6,843 patients), below the LAD (20.3%), ICB (19.0%), and England (17.9%). Based on Census usual residents rather than registered patients, 96.2% are White (LAD 95.3%, ICB 93.0%, England 81.1%), leaving a 3.8% ethnic minority share. Projected list growth to 2030 is 2.2% under an unverified model.
Age profile
65+: ICB 19.0%, England 17.9%
Ethnicity
Older people · falls rows are Cheshire West and Chester (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Cheshire West and Chester LA) | 2,109 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 78.1% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 50.4% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Cheshire West and Chester LA) | 893 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Cheshire West and Chester LA) | 14.9 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation reaches 30.7% PCN-wide, ranging from 26.9% to 47.0% across practices
Winsford PCN has 30.7% of registered patients in the Core20 most deprived quintile, exceeding Cheshire West and Chester (15.7%) and England (21.0%), and below the ICB (31.9%). Modelled practice shares average 31.5%, an unresolved 0.87 percentage point discrepancy. All five practices exceed England, ranging 20.1 pp: concentration peaks at Launceston Close Surgery (47.0%, 2,555 patients), while Swanlow Medical Centre carries the largest volume (3,286 patients, 31.3%). This split requires balancing intensive engagement at high-concentration practices with structured clinical recall across high-volume lists.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
385
SMI register
0.99% recorded prevalence
314
Learning disability register
0.81% recorded prevalence
8
Care homes, 252 beds
In the PCN catchment
9.6%
Provide unpaid care
Cheshire West and Chester (LAD), Census 2021
The PCN records 314 patients on the learning disability register (0.8% prevalence vs 0.5% LAD, 0.6% ICB, and 0.6% England) and 385 on the severe mental illness register (1.0% vs 1.0% LAD, 1.1% ICB, and 1.0% England). Catchment facilities include 8 care homes with 252 beds.
Severe mental illness: physical health checks
SMI physical health checks fell over three years: BP checks fell 8.9 pp to 79.9% (England 83.4%, +4.4 pp), alcohol recording fell 7.3 pp to 80.5%, and BMI fell 7.0 pp to 82.0%. Coordinated recall could recover monitoring.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
6,629
Hypertension register
+4.31%
Register growth, 3 yrs
Cheshire West and Chester (LAD) +6.60% · England +5.60%
−4.09pp
BP control, under 80
≤140/90 · −2.15pp aged 80+
+819
More patients by 2030
Forecast 7,448 (18.62%)
Hypertension case-finding and control
Hypertension prevalence is 17.1% (6,629 patients), above England (15.2%), Cheshire West and Chester (17.0%), and NHS Cheshire and Merseyside Integrated Care Board (16.8%). Current blood pressure control is 72.2% (England 70.3%) and blood pressure under 140/90 mmHg for under-80s is 71.3% (England 67.8%). However, three-year trajectories trail benchmarks: control in under-80s fell 4.1 pp over 2023 to 2025 (England +2.1 pp), and treatment to target fell 4.9 pp (England +2.5 pp). Denominators include personalised care adjustments. Declining blood pressure control against rising national benchmarks indicates a need to systematically recall hypertensive patients whose monitoring has lapsed.
Lipids and statins
Lipid-lowering therapy in high-risk patients reaches 71.4% for QRISK ≥ 20%, exceeding England (63.6%), Cheshire West and Chester (63.8%), and NHS Cheshire and Merseyside Integrated Care Board (63.2%). Therapy in chronic kidney disease reaches 75.4% (England 70.3%). Denominators include personalised care adjustments.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 92,244 | £1.80 | £1.71 | £1.86 | £166,039 |
| Cardiovascular (all), 2025 | 114,077 | £3.69 | £4.37 | £3.33 | £420,944 |
In 2026, 92,244 lipid-regulating drug items were prescribed at £1.80 per item (spend £166,039). The PCN spent £5,535 less than at England's unit cost (£1.86), but £8,302 more than at NHS Cheshire and Merseyside Integrated Care Board's unit cost (£1.71). Unit cost is not efficiency.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−6.75%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−1.62%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 7.9% (2,877 patients), above England (6.6%), and COPD prevalence is 3.0% (England 1.9%). Asthma management prescribing for ages 5-19 is 2,372 per 1,000 (England 1,488). Over 2023 to 2025, asthma reviews fell 4.5 pp to 61.7% (England 65.7%, +2.8 pp), leaving about 1,100 patients unreviewed. COPD reviews reach 75.5% (England 76.4%). Denominators include personalised care adjustments.
Cancer register and children's immunisation
Cancer prevalence is 3.7% (1,449 patients), below Cheshire West and Chester (4.8%) and England (3.8%). Age-5 MMR dose 2 reaches 96.1% (England 82.8%) and 4-in-1 booster coverage reaches 93.2% (England 80.9%), 1.8 pp below the 95.0% target. At High Street Practice Winsford, age-5 MMR second-dose coverage trails first-dose uptake by 8.7 pp (91.3% versus 100.0%).
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.5%
Cheshire and Merseyside ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,640
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Cheshire and Merseyside ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 11% | 2,354 |
| Breast | 87.1% | 85.4% | 11% | 2,083 |
| Prostate | 52.3% | 53.2% | 12% | 2,037 |
| Bowel | 44.9% | 47.0% | 16% | 1,674 |
| Skin cancer | 86.9% | 87.8% | 21% | 932 |
In 2022, across NHS Cheshire and Merseyside ICB, 55.5% of cancers with a known stage (7,482 of 13,490) were diagnosed at stage 1 or 2, in line with England (55.3%) but 19.5 pp below the 75.0% national ambition. Known-stage completeness was 72.8% (13,490 of 18,522 registered cancers; England 67.0%). Reaching the 75.0% ambition would require about 2,640 additional early-stage diagnoses annually across the ICB. Early-stage shares varied from 87.1% in breast to 22.0% in oesophageal cancer, though some tumor types have small counts. These reflect ICB-level completeness rather than PCN performance. System-wide staging shortfalls mean primary care early detection and screening remain essential levers.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026, Mid Cheshire Hospitals NHS Foundation Trust met the 28-day faster diagnosis standard at 80.0% (standard 75.0%), against 87.4% at Countess of Chester Hospital NHS Foundation Trust, 80.2% at North Cheshire and Mersey NHS Foundation Trust, 77.2% across the ICB, and 79.3% in England. However, Mid Cheshire trailed the 85.0% 62-day standard at 71.1% (ICB 76.2%, England 71.2%) and the 96.0% 31-day standard at 86.2% (ICB 95.7%, England 92.5%). Diagnostic 6-week waits at Mid Cheshire were 5.2% for MRI and 1.1% for CT, below England (21.4% and 9.9%).
| Pathways within standard (%) | Mid Cheshire | North Cheshire and Mersey | Countess of Chester | Cheshire and Merseyside ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 79.95 | 80.21 | 87.37 | 77.25 | 79.32 |
| 31-day treatment (96%) | 86.21 | 98.17 | 93.48 | 95.71 | 92.50 |
| 62-day referral to treatment (85%) | 71.12 | 83.67 | 83.28 | 76.23 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Mid Cheshire | North Cheshire and Mersey | Countess of Chester | England |
|---|---|---|---|---|
| MRI | 5.15 | 0.53 | 11.26 | 21.40 |
| CT | 1.09 | 2.32 | 4.18 | 9.92 |
| Echocardiography | 5.51 | 28.04 | 31.44 | 28.48 |
| Colonoscopy | 30.34 | 15.98 | 26.44 | 30.83 |
| Gastroscopy | 31.89 | 20.24 | 27.52 | 29.02 |
| All 15 DM01 tests | 12.72 | 6.34 | 20.16 | 23.14 |
| Community services activity | Cheshire West and Chester residents | Cheshire and Merseyside ICB |
|---|---|---|
| Care contacts | 47,655 | 541,280 |
| Referrals | 10,325 | 97,150 |
| Patients with a contact | 18,585 | 146,240 |
Community services (residents of Cheshire West and Chester), Jun 2026 (provisional). In June 2026, community services recorded 47,655 contacts with Cheshire West and Chester residents. Adults aged 65 and over accounted for 25,095 of these contacts, representing 52.7% of all recorded activity. These figures capture borough-wide resident activity from the Community Services Dataset rather than PCN-specific contacts, illustrating the high share of community service resource dedicated to older residents across the wider local authority.
Practice variation and patient experience
Phone contact varies by 37.8 pp across practices while overall satisfaction exceeds England
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Weaver Vale | 129 | 26.9 | 88.4% | 79.6% | 89.4% |
| Willow Wood | 144 | 27.7 | 80.1% | 72.0% | 86.7% |
| Launceston Close | 128 | 47.0 | 85.7% | 80.7% | 85.3% |
| High Street | 111 | 29.8 | 76.6% | 83.3% | 84.9% |
| Swanlow | 118 | 31.3 | 50.6% | 71.5% | 81.3% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
19 of 25 three-year trajectories trail England across routine reviews and checks
Across 25 tracked measures, 19 three-year trajectories trail England. Severe mental illness checks fell over 2023 to 2025: blood pressure recording fell 8.9 pp (England +4.4 pp), alcohol recording fell 7.3 pp (England +5.4 pp), and BMI recording fell 7.0 pp (England +5.1 pp). Heart failure reviews fell 6.8% (England +8.7%) and dementia prevalence fell 8.8% (England +6.0%). Relative three-year gains include breast screening (+10.6% vs +8.4% England) and statins in diabetes with cardiovascular disease (+2.0% vs +1.0% England). Lags may reflect review capacity or coding, unverified locally.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Dementia register
BP check (SMI)
Alcohol record (psychosis)
BMI record (SMI)
Breast screening (53-70)
Diabetes statin (CVD)
Diabetes statin (no CVD)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Cheshire West and Chester (LAD) | Asset | PCN | Cheshire West and Chester (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 8 (252 beds) | n/a | Schools (catchment) | 30 | n/a |
| Children's centres | 2 | 15 | Places of worship | 21 | 231 |
| Libraries | 1 | 16 | Food banks (VCS) | n/a | 1 |
| Homelessness support (VCS) | n/a | 1 | Day centres (VCS) | n/a | 1 |
| Carers support groups (VCS) | n/a | 1 | Primary schools (LA maintained) | 6 | 70 |
| Primary academies | 6 | 46 | Special schools | 1 | 5 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Standardised annual asthma review recall
Asthma 12-month review (incl. PCAs) is 61.7% across 2,877 patients versus 65.7% in England (3.9 pp below) and 62.3% in the ICB, falling 4.5 pp over 2023 to 2025 (England +2.8 pp) and leaving 1,101 (about 1,100) unreviewed. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Coordinated SMI physical health checks
On the 385-patient SMI register, 12-month BP checks fell 8.9 pp over 2023 to 2025 to 79.9% (England 83.4%, +4.4 pp; LAD 81.0%, +1.8 pp); alcohol recording fell 7.3 pp to 80.5% and BMI fell 7.0 pp to 82.0%. Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Option 3
Diabetes and hypertension control recall
In 2024/25, non-frail diabetes HbA1c <= 58 mmol/mol is 50.4% (1,082/2,147; England 57.4%, ICB 56.2%) and frail <= 75 mmol/mol is 78.1% (563/721; England 81.9%); under-80 hypertension BP control (71.3%) fell 4.1 pp (England +2.1 pp). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Two-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical check recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension blood pressure recall audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Targeted cervical screening recall (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Telephony and access workflow review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Standardised annual asthma review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Core20 cohort (IMD quintile 1) | Core20PLUS5 respiratory | PCN & Practice |
| Option 2 · Coordinated SMI physical health checks (p12) | Severe mental illness register · SMI register with a BP check in the last 12 months · Record of a BP check in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN & Practice |
| Option 3 · Diabetes and hypertension control recall (p12) | Diabetes without frailty: HbA1c at or below 58 mmol/mol · Diabetes with frailty: HbA1c at or below 75 mmol/mol · IFCC-HbA1c <= 58 mmol/mol in patients with diabetes without frailty (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
